Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that
concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further
decrease the rate of disease progression and improve the survival outcome of patients with
unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with
concurrent chemo-radiotherapy alone.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Fifth Affiliated Hospital, Sun Yat-Sen University Wuzhou Red Cross Hospital Yuebei People's Hospital Zhongshan People's Hospital, Guangdong, China